Manufacturing Networks Are Now the Commercialization Battleground

Biotech commercialization now hinges on controlling the manufacturing network—sites, partners, and capacity—needed to launch reliably, scale quickly, and reduce supply risk.

• •CDMOs and biomanufacturers are expanding capacity to win launch-ready work in complex modalities.
• •Network control is becoming a competitive moat, not just process transfer or outsourcing.
• •Geographic redundancy and multi-site GMP access reduce single-point failure and speed market entry.
• •Stable, modular, and transferable production platforms are gaining value as commercialization tools.
• •Investors are favoring infrastructure that turns regulatory readiness into dependable supply.